Diagnostic and prognostic value of serum prostate specific antigen in prostate carcinoma

Hellenic Journal of Nuclear Medicine

Volumn 7, Issue 3, 2004, Pages 146-148

  Grammaticos, Philip ^a  

^a NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ANTIGEN DETECTION; CANCER MORTALITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; EDITORIAL; HIGH RISK PATIENT; HUMAN; MALE; PROGNOSIS; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; REFERENCE VALUE;

EID: 13244267020     PISSN: 00258024     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (12)

1. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med 2003; 30: 1378-1382.
2. Carter B. Prostate cancers in men with low PSA levels - Must we find them? N Engl J Med 2004; 350: 2292-2294.
3. Punglia R, D'Amico A, Catalona W, et al. Effect of verification bias on screening for prostate cancer by measurement of prostate- specific antigen. N Engl J Med 2003; 349: 335-342.
4. Shroder F, Kranse R. Verification bias and the prostate specific antigen test - Is there a case for a lower threshold biopsy? (Ed.). N Engl J Med 2003; 349: 393-395.
5. D'Amico A, Ming Hui Chen, Kimberly A, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351: 125-135.
6. Glaser AI. Prostate cancer with low PSA levels (C). N Engl J Med 2004; 351: 1802.
7. Thompson IM, Goodman P, Tangen C, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-221.
8. Petrylak D, Tangen, G, Maha P, et al. Doxatel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
9. Small EJ. Prostate cancer. In: Cecil's textbook of medicine. Goldman L and Ausiello D editors, 22nd edn. Philadelphia, Saunders, chapter 207: 1243-1247.
10. Hybritech Europe S.A. Prospectus. An accurate biological marker for use in the management of patients with prostate cancer. Tandem®-R PSA. 1995, p. 1-4.
11. Greek source. 2001, 67: 17-23.
12. Conte C. Prostate cancer: to screen or not. NRTA Bulletin 2001; 42: 7-8.